Flu antibodies are immune proteins produced in response to influenza virus infections or vaccinations. They bind to antigenic sites on viral surface proteins—hemagglutinin (HA) and neuraminidase (NA)—to neutralize infection or mitigate disease severity. These antibodies are critical for understanding vaccine efficacy and therapeutic interventions, as demonstrated by antigenic characterization studies and clinical trials .
Flu antibodies can be broadly categorized by their binding regions and functional mechanisms:
HA Head Antibodies:
HA Stem Antibodies:
NA Head Antibodies:
NA "Dark Side" Antibodies:
Flu antibodies neutralize viruses through direct and indirect mechanisms:
CR9114:
1G01:
Flu-IVIG (Intravenous Immunoglobulin):
VIR-2482:
mRNA-1010:
Antigenic Drift/Shift: HA head antibodies’ limited cross-reactivity necessitates annual vaccine updates .
NA Antibody Dynamics: NA-specific immunity is less understood but critical for reducing transmission .
Therapeutic Gaps: No approved antibody therapies exist for influenza A, highlighting the need for broadly protective candidates like CR9114 or 1G01 .
The polyclonal flu antibody production involves a multi-step process. First, the recombinant Escherichia coli (strain K12) flu protein (amino acids 804-1039) is selected as the immunogen. This immunogen is administered to a rabbit through injections, repeated several times to elicit an immune response. Subsequently, the rabbit's B cells produce a significant amount of antibodies, primarily of the IgG isotype. These antibodies are then harvested from the rabbit serum and purified using protein G affinity chromatography. The flu antibody possesses the ability to react with the flu protein derived from Escherichia coli (strain K12). The purified flu antibody has been rigorously validated through ELISA and Western blot applications.
Escherichia coli flu protein (Ag43) is a phase-variable outer membrane protein playing a crucial role in the autoaggregation, flocculation, and colony morphology of E. coli K12 strains [1-4]. Ag43-mediated aggregation is macroscopically observable as cell flocculation in liquid suspensions [5]. Furthermore, Ag43 has been implicated in promoting the persistence of uropathogenic E. coli isolates within the urinary tract, underscoring its significance in bacterial virulence and pathogenesis [6]. Research has demonstrated that Ag43 facilitates specific bacterial uptake and survival within human neutrophils, highlighting its role in bacterial evasion of the host immune response [5].
References:
[1] Schembri, M., & Klemm, P. (2001). Coordinate gene regulation by fimbriae-induced signal transduction. The Embo Journal, 20(12), 3074-3081. https://doi.org/10.1093/emboj/20.12.3074
[2] Klemm, P., Hjerrild, L., Gjermansen, M., & Schembri, M. (2003). Structure‐function analysis of the self‐recognizing antigen 43 autotransporter protein from escherichia coli. Molecular Microbiology, 51(1), 283-296. https://doi.org/10.1046/j.1365-2958.2003.03833.x
[3] Krisandi, G., & Prayogo, S. (2021). Analisis potensi nanopartikel seng oksida sebagai terapi alternatif terhadap uropathogenic escherichia coli penyebab infeksi saluran kemih. Jimki Jurnal Ilmiah Mahasiswa Kedokteran Indonesia, 9(1), 38-47. https://doi.org/10.53366/jimki.v9i1.278
[4] Henderson, I., Meehan, M., & Owen, P. (1997). Antigen 43, a phase-variable bipartite outer membrane protein, determines colony morphology and autoaggregation in escherichia coli k-12. Fems Microbiology Letters, 149(1), 115-120. https://doi.org/10.1111/j.1574-6968.1997.tb10317.x
[5] Fexby, S., Bjarnsholt, T., Jensen, P., Roos, V., Høiby, N., Givskovet al. (2007). Biological trojan horse: antigen 43 provides specific bacterial uptake and survival in human neutrophils. Infection and Immunity, 75(1), 30-34. https://doi.org/10.1128/iai.01117-06
[6] Lüthje, P., & Brauner, A. (2010). Ag43 promotes persistence of uropathogenic escherichia coli isolates in the urinary tract. Journal of Clinical Microbiology, 48(6), 2316-2317. https://doi.org/10.1128/jcm.00611-10
KEGG: ecj:JW1982
STRING: 316385.ECDH10B_2146